Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 8/20 | 0.38 |
| ▸ | F2RL3 | Q96RI0 | 2/20 | 0.33 |
| ▸ | TNKS | O95271 | 2/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.33 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.33 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.31 |
| ▸ | UTRN | P46939 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | ARF6 | P62330 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20837244 | 0.93 | APLNR (0.34) | APLNRF2RL3TNKSTNKS2PARP2 | |
| SCHEMBL20914351 | 0.93 | TNKS (0.35) | APLNRF2RL3TNKSTNKS2PARP2 | |
| SCHEMBL20914342 | 0.92 | F2RL3 (0.33) | APLNRF2RL3TNKSTNKS2PARP2 | |
| SCHEMBL20913955 | 0.90 | APLNR (0.34) | APLNRF2RL3TNKSTNKS2PARP2 | |
| SCHEMBL20837245 | 0.90 | APLNR (0.33) | APLNRF2RL3TNKSTNKS2PARP2 | |
| SCHEMBL20913906 | 0.89 | F2RL3 (0.39) | APLNRF2RL3TNKSTNKS2PARP2 | |
| SCHEMBL20914132 | 0.89 | APLNR (0.33) | APLNRF2RL3TNKSTNKS2PARP2 | |
| SCHEMBL20913986 | 0.88 | TNKS (0.35) | APLNRF2RL3TNKSTNKS2PARP2 | |
| SCHEMBL20913914 | 0.88 | APLNR (0.33) | APLNRF2RL3TNKSTNKS2PARP2 | |
| SCHEMBL20914135 | 0.87 | F2RL3 (0.35) | APLNRF2RL3TNKSTNKS2PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738056-B2 | Pyrazolopyrimidinone compounds and uses thereof | ADURO BIOTECH INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-10738056-B2 | Pyrazolopyrimidinone compounds and uses thereof | ADURO BIOTECH INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190119285-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF | CHINOOK THERAPEUTICS, INC. | 2019-04-25 | — | — | US | disclosed |
| US-20190119285-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF | CHINOOK THERAPEUTICS, INC. | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738056-B2 | Pyrazolopyrimidinone compounds and uses thereof | NLRP3, NLRP1, P2RX7 | APLNR 3114/4885F2RL3 1469/4885TNKS 531/4885 |
| US-20190119285-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF | NLRP3, NLRP1, P2RX7 | APLNR 3114/4885F2RL3 1469/4885TNKS 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.